Aim: We investigate the assessment method to detect the early stage of amnestic mild cognitive impairment (aMCI) using Wechsler Memory Scale – Revised (WMS-R) and Wechsler Adult Intelligence Scale – Third Edition (WAIS-III). Methods: Three groups (normal group, aMCI group, and early aMCI group), controlled for age and years of education, underwent brain 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET), WAIS-III, WMS-R, and other tests. The early aMCI group does not fulfill the clinical diagnostic criteria of aMCI because patients do not have objective memory impairment, but their clinical symptoms and results of 18F-FDG PET indicate that they should be included in the category of aMCI. Results: The discrepancy of scores between Verbal IQ and General Memory had the highest accuracy in discriminating between normal and early aMCI groups. Conclusion: The cutoff point determined in this study is useful to detect an early stage of aMCI, which may be distinguished from aMCI using the current criteria.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B: Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985–1992.
Perri R, Serra L, Carlesimo GA, Caltagirone C, Early Diagnosis Group of Italian Interdisciplinary Network on Alzheimer’s Disease: Preclinical dementia: an Italian multicentre study on amnestic mild cognitive impairment. Dement Geriatr Cogn Disord 2007;23:289–300.
Petersen RC, Negash S: Mild cognitive impairment: an overview. CNS Spectr 2008;13:45–53.
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–308.
Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, et al: Mild cognitive impairment. Lancet 2006;367:1262–1270.
Kryscio RJ, Schmitt FA, Salazar JC, Mendiondo MS, Markesbery WR: Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology 2006;66:828–832.
Loewenstein DA, Acevedo A, Agron J, Duara R: Stability of neurocognitive impairment in different subtypes of mild cognitive impairment. Dement Geriatr Cogn Disord 2006;23:82–86.
Lee KS, Cho HS, Hong CH, Kim DG, Oh BH: Differences in neuropsychiatric symptoms according to mild cognitive impairment subtypes in the community. Dement Geriatr Cogn Disord 2008;26:212–217.
Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR: Neuropathologic substrate of mild cognitive impairment. Arch Neurol 2006;63:38–46.
Murayama N, Iseki E, Fujishiro H, Yamamoto R, Ota K, Suzuki M, Nagashima K, Arai H, Sato K: Detection of early amnestic mild cognitive impairment without significantly objective memory impairment: a case-controlled study. Psychogeriatrics 2010;10:62–68.
Wechsler D: Wechsler Adult Intelligence Scale – Third Edition. San Antonio, The Psychological Corporation, 1997.
Fujita K, Maekawa H, Dairoku K, Yamanaka K: A Japanese Version of the WAIS-III (in Japanese). Tokyo, Nihon Bunka Kagakusha, 2006.
Murayama N, Iseki E, Tagaya H, Ota K, Kasanuki K, Fujishiro H, Arai H, Sato K: Which is more correlated with memory function in Japanese normal elderly subjects: intelligence or years of education? Psychogeriatrics, in press.
Wechsler D: Wechsler Memory Scale – Revised. San Antonio, The Psychological Corporation, 1987.
Sugishita M: Manual for the Japanese Version of Wechsler Memory Scale – Revised (in Japanese). Tokyo, Nihon Bunka Kagakusya, 2001.
Iseki E, Murayama N, Yamamoto R, Fujishiro H, Suzuki M, Kawano M, Miki S, Sato K: Construction of a 18F-FDG PET normative database of Japanese healthy elderly subjects and its application to demented and mild cognitive impairment patients. Int J Geriatr Psychiatry 2010;25:352–361.
Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566–572.
Reisberg B, Ferris SH, de Leon MJ, Crook T: The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136–1139.
Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
Kennedy AM, Frackowiak RS, Newman SK, Bloomfield PM, Seaward J, Roques P, Lewington G, Cunningham VJ, Rossor MN: Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer’s disease. Neurosci Lett 1995;186:17–20.
Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE: Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 1997;42:85–94.
Lange RT, Chelune GJ: Application of new WAIS-III/WMS-III discrepancy scores for evaluating memory functioning: relationship between intellectual and memory ability. J Clin Exp Neuropsychol 2006;28:592–604.
Tulsky DS, Saklofske DH, Wilkins C, Weiss LG: Development of a general ability index for the Wechsler Adult Intelligence Scale – Third Edition. Psychol Assess 2001;13:566–571.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.